



Immune-Mediated Colitis with Concurrent Clostridium Difficile Infection

⁶Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow 111123, Russia

⁷Professor, Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow 111123, Russia

Abstract

Immune checkpoint inhibitors (ICIs) are widely used for patients with primary lung cancer in the recent years and have better overall survival versus previously used chemotherapy [1]. Some adverse events of immunotherapy, such as diarrhea and colitis, can lead to treatment discontinuation due to the risk of fatal outcome. We present the case of pembrolizumab-induced colitis with concurrent clostridium difficile infection (CDI) in a patient with metastatic non-small cell lung cancer (NSCLC) [2,3]. 58-year-old man was hospitalized due to the symptoms of persisting watery diarrhea and diffuse abdominal pain. Laboratory tests on the day of admission were significant for mild iron deficiency anemia, hypoalbuminemia, hypoproteinemia, leukocytosis, and increased C-reactive protein (68,94 mg/L) [4]. His stool polymerase chain reaction (PCR) test was positive for Clostridium difficile A and B toxins [5,6]. The treatment for CDI had started with intravenous metronidazole (500 mg every 8 hours) and intravenous vancomycin (1000 mg every 12 hours). Flexible sigmoidoscopy detected edema, erythema, fibrin-covered erosions, loss of vascular pattern in sigmoid colon and rectum. Histological evaluation of the biopsy revealed increased lamina propria cellularity, glandular apoptotic changes, crypt abscesses, shortening, mucin cells depletion and increased number of intraepithelial lymphocyte (Figure 1). Most of them were CD3(+) cytotoxic T-lymphocytes (Figure 2). However, his symptoms failed to improve with antibiotics management. Due to the ongoing treatment with pembrolizumab and the lack of response to the severe CDI antibiotic treatment, the diagnosis of an IMC was made. After excluding an infection with cytomegalovirus, EBV by PCR in colonic tissue, an immunosuppression with intravenous prednisolone 120 mg daily was initiated. His diarrhea began to improve, abdominal pain resolved, and CRP levels decreased in six days. All patients receiving ICIs with diarrhea and infection should be suspected of immune-mediated colitis (IMS).

References

1. Suresh K, Naidoo J, Lin C, Danof S (2018) Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. *Chest* 154: 1416-1423.
2. Wei X, Yunfeng Z, He D, Xuejun G (2021) Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. *Front Oncol*.
3. Palmieri DJ, Carlino MS (2018) Immune Checkpoint Inhibitor Toxicity. In *Current Oncology Reports*
4. Abu-Sbeih H, Ali FS, Wang Y (2020) Immune-checkpoint inhibitors induced diarrhea and colitis: A review of incidence, pathogenesis and management. *Curr Opin Gastroenterol* 36: 25-32.
5. Zhou C, Klionsky Y, Treasure ME, Bruno DS (2019) Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection. *Case Rep Oncol* 12: 164-170.
6. Rodríguez GA, Merida GA, Muñoz UN, Galera LMM, Orellana, M et al. (2015) Risk factors associated with Clostridium difficile infection in adult oncology